Description
Children and young adults up to age 25 with High-Risk B-cell acute lymphoblastic leukemia (B-ALL) sought for a study of an investigational drug in combination of chemotherapy based on individual disease characteristics to improve 5-year disease-free survival (DFS).
Overview
Based on their disease characteristics, participants will receive either the standard chemotherapy or an combination of chemotherapy and an investigational to better understand how to improve treatment outcomes for children and young adults with newly diagnosed High-Risk (HR) B-cell acute lymphoblastic leukemia (B-ALL).
What we're hoping for
To evaluate if an investigational combination of chemotherapy drugs improves outcomes in children and young adults with newly diagnosed High-Risk (HR) B-cell acute lymphoblastic leukemia (B-ALL).
Additional Information
ClinicalTrials.gov Identifier: NCT03959085